CN105168732B - A kind of application of the Chinese medicine composition of replenishing kidney and strengthening bone in the drug that bone joint pain caused by arimedex is treated in preparation - Google Patents
A kind of application of the Chinese medicine composition of replenishing kidney and strengthening bone in the drug that bone joint pain caused by arimedex is treated in preparation Download PDFInfo
- Publication number
- CN105168732B CN105168732B CN201510530639.5A CN201510530639A CN105168732B CN 105168732 B CN105168732 B CN 105168732B CN 201510530639 A CN201510530639 A CN 201510530639A CN 105168732 B CN105168732 B CN 105168732B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- application
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 210000003734 kidney Anatomy 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000005728 strengthening Methods 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title claims description 20
- 208000006820 Arthralgia Diseases 0.000 title description 12
- 208000002193 Pain Diseases 0.000 claims abstract description 32
- 241000218176 Corydalis Species 0.000 claims abstract description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 6
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 4
- 244000197580 Poria cocos Species 0.000 claims description 13
- 235000008599 Poria cocos Nutrition 0.000 claims description 13
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 241000209020 Cornus Species 0.000 claims description 12
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 241000132171 Phryma leptostachya Species 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 20
- 208000018934 joint symptom Diseases 0.000 abstract description 5
- 239000003886 aromatase inhibitor Substances 0.000 abstract description 3
- 229940046844 aromatase inhibitors Drugs 0.000 abstract 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 235000021508 Coleus Nutrition 0.000 abstract 1
- 244000061182 Coleus blumei Species 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract 1
- 235000013372 meat Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 description 13
- 206010006187 Breast cancer Diseases 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 244000170916 Paeonia officinalis Species 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 229960002932 anastrozole Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009261 endocrine therapy Methods 0.000 description 3
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 3
- 229960000255 exemestane Drugs 0.000 description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 210000002478 hand joint Anatomy 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 240000004510 Agastache rugosa Species 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000048199 Hibiscus mutabilis Species 0.000 description 1
- 235000003973 Hibiscus mutabilis Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229940057802 caltrate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- -1 granula Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000009184 walking Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种益肾健骨的中药组合物在制备治疗芳香化酶抑制剂导致的骨关节症状的药物中的应用，所述中药组合物的原料药组成为：熟地150‑250份，山萸肉100‑200份，菟丝子60‑150g，川牛膝100‑200份，香附70‑160份，当归70‑150份，茯苓100‑200份，白芍100‑200份，川芎60‑150份，延胡索100‑200份，透骨草100‑200份，络石藤150‑250份。临床试验研究发现本发明所述中药组合物可以用于治疗芳香化酶抑制剂的疼痛、骨关节炎、手类风湿性关节炎。The invention discloses an application of a traditional Chinese medicine composition for nourishing the kidney and strengthening bones in the preparation of a medicine for treating bone and joint symptoms caused by aromatase inhibitors. 100‑200 portions of dogwood meat, 60‑150g of dodder, 100‑200 portions of Achyranthes sichuanensis, 70‑160 portions of Cyperus officinalis, 70‑150 portions of Angelica, 100‑200 portions of Poria, 100‑200 portions of Paeonia lactiflora, 60‑200 portions of Chuanxiong 150 copies, 100-200 copies of Corydalis fragrans, 100-200 copies of Tougucao, and 150-250 copies of Coleus vines. Clinical trials have found that the traditional Chinese medicine composition of the present invention can be used for the treatment of pain, osteoarthritis and hand rheumatoid arthritis caused by aromatase inhibitors.
Description
Technical field
The present invention relates to a kind of new application of the Chinese medicine composition of replenishing kidney and strengthening bone, in particular in a kind of replenishing kidney and strengthening bone
Application of the drug composition in the drug that bone joint pain caused by arimedex is treated in preparation.
Background technique
Breast cancer is one of the most common type and main lethal cancer kind in female malignant.According to the World Health Organization
The estimation of GLOBOCAN 2012 of International Cancer Research Center publication, the new diagnosed case of global women with breast cancer about 170 in 2012
Ten thousand, dead 52.2 ten thousand.In China, breast cancer occupies the 1st of female cancer morbidity, and annual new cases about 210,000 are dead
Rate 8.65/10 ten thousand occupies the 6th of female cancer death.Currently, the treatment means of breast cancer are mainly based on operative treatment,
It is postoperative to be aided with chemotherapy, radiotherapy and endocrine therapy.According to statistics, about 75% patient with breast cancer's hormone receptor positive, needs to connect
By endocrine therapy.
Third generation arimedex is the standard drug of Postmenopausal Breast Cancer patient's endocrine therapy.It is international multiple
Clinical trial result confirms: arimedex has the curative effect and preferably tolerance compared with tamoxifen more precisely
Property, extend the recurrence-free survival time, risk of recurrence reduces, the decline of opposite side incidence of breast cancer.It takes for a long time caused by AIs
Bones and joints symptom (aromatase inhibitor-associated musculoskeletal symptoms, AIMSS) hair
Sick rate is up to 50%, has seriously affected the quality of life of patient with breast cancer and the compliance to AIs treatment.The hair of AIMSS at present
Interpretation of the cause, onset and process of an illness system and treatment method are all still in the research and probe stage, and due to lacking effective intervening measure, AIMSS will be in suspension
One big hidden danger of secretion treatment and tumor recurrence.
China's traditional Chinese medicine has the characteristics of Small side effects, wholistic therapy and conditioning, can effectively improve the state of an illness of patient.
Summary of the invention
Present invention aims at the Chinese medicine compositions for disclosing a kind of replenishing kidney and strengthening bone to lead in preparation treatment arimedex
Application in the drug of the bone joint pain of cause.
Object of the present invention is to what is be achieved through the following technical solutions: the bulk pharmaceutical chemicals composition and parts by weight of the pharmaceutical composition
Are as follows: 150-250 parts of radix rehmanniae preparata, 100-200 parts of pulp of dogwood fruit, Semen Cuscutae 60-150g, 100-200 parts of radix cyathulae, 70-160 parts of rhizoma cyperi,
It is 70-150 parts of Radix Angelicae Sinensis, 100-200 parts of Poria cocos, 100-200 parts of Radix Paeoniae Alba, 60-150 parts of Rhizoma Chuanxiong, 100-200 parts of rhizoma corydalis, deep
It is 100-200 parts careless, 150-250 parts of caulis trachelospermi.
Chinese medicine composition of the present invention can be with are as follows:
180-220 parts of radix rehmanniae preparata, 120-180 parts of pulp of dogwood fruit, Semen Cuscutae 80-120g, 120-180 parts of radix cyathulae, rhizoma cyperi 80-
150 parts, 80-130 parts of Radix Angelicae Sinensis, 120-180 parts of Poria cocos, 120-180 parts of Radix Paeoniae Alba, 80-130 parts of Rhizoma Chuanxiong, 120-180 parts of rhizoma corydalis,
120-180 parts of lopseed, 160-220 parts of caulis trachelospermi.
Chinese medicine composition of the present invention is preferred are as follows:
The bulk pharmaceutical chemicals of the pharmaceutical composition are as follows: 200 parts of radix rehmanniae preparata, 150 parts of pulp of dogwood fruit, 100 parts of Semen Cuscutae, radix cyathulae 150
Part, 100 parts of rhizoma cyperi, 100 parts of Radix Angelicae Sinensis, 150 parts of Poria cocos, 150 parts of Radix Paeoniae Alba, 100 parts of Rhizoma Chuanxiong, 150 parts of rhizoma corydalis, lopseed 150
Part, 200 parts of caulis trachelospermi.
Chinese medicine composition of the present invention can also be preferred are as follows: and 190 parts of radix rehmanniae preparata, 170 parts of pulp of dogwood fruit, Semen Cuscutae 110g,
120 parts of radix cyathulae, 130 parts of rhizoma cyperi, 120 parts of Radix Angelicae Sinensis, 170 parts of Poria cocos, 130 parts of Radix Paeoniae Alba, 120 parts of Rhizoma Chuanxiong, 130 parts of rhizoma corydalis, thoroughly
160 parts, 190 parts of caulis trachelospermi of bone grass.
Chinese medicine composition of the present invention can also be preferred are as follows: and 180 parts of radix rehmanniae preparata, 120 parts of pulp of dogwood fruit, Semen Cuscutae 80g,
It is 180 parts of radix cyathulae, 140 parts of rhizoma cyperi, 90 parts of Radix Angelicae Sinensis, 130 parts of Poria cocos, 170 parts of Radix Paeoniae Alba, 90 parts of Rhizoma Chuanxiong, 170 parts of rhizoma corydalis, deep
130 parts, 170 parts of caulis trachelospermi of grass.
Various dosage forms are made using techniques known in the Chinese medicine composition, dosage form be capsule,
The pharmaceutically acceptable dosage form such as granula, tablet, pill, powder.
It is preferred that granule, capsule, pill or tablet.
The preparation method of the Chinese medicine composition, this method can be with are as follows: flavour of a drug add water to cook, and filter, and concentration adds auxiliary
Material is appropriate, mixes, dry, granulation to get.
The preparation method of the Chinese medicine composition, it is characterised in that this method is preferred are as follows: flavour of a drug add water to cook 2 times, the
60min, the 2nd 30min are filtered, and concentration adds right amount of auxiliary materials, mixes, dry, granulation to get.
The present invention is the prescription that inventor is had found by many years clinical practice, reinforces the kidney to strengthen the bone, adjusts liver dredging collateral.Our radix rehmanniae preparata
Yellow enriching yin and nourishing kidney, life essence-filling, marrow-benefitting；Rhizoma cyperi soothing liver-qi stagnation, regulating the flow of QI to ease the stomach are altogether monarch drug in a prescription.Fructus Corni, Semen Cuscutae, radix cyathulae tonifying liver
The benefits of kidney, strong waist and knee, hard muscles and bones, three medicines and radix rehmanniae preparata compatibility play replenishing kidney, strengthening waist strong bone altogether；Radix Angelicae Sinensis is sweet bitter and warm, blood-nourishing and blood, white
Yin is held back in Chinese herbaceous peony blood-nourishing, soft liver emergency, is returned, Chinese herbaceous peony and rhizoma cyperi are with using, tonifying liver body and help liver to use, make blood and then to fill then liver soft for liver and, blood,
It is ministerial drug.Wood is strongly fragrant not up to spleen insufficiency is caused, and Gu Zuo is with Poria cocos strengthening the spleen and replenishing qi, and real soil is with imperial wood insult.Radix rehmanniae preparata, returning Chinese herbaceous peony etc., yin is soft
The product enriched blood are equipped with the Rhizoma Chuanxiong promoting flow of qi and blood circulation, and sound is suitable, mend without stagnant.Rhizoma corydalis work hard it is warm-natured enter Liver Channel, in promoting circulation of blood the stagnation of the circulation of vital energy with
Up to the function of promoting flow of qi and blood circulation analgesic.Lopseed, caulis trachelospermi return liver kidney channel, remove obstruction in channels to relieve pain, and are all adjutant.
Chinese medicine composition of the present invention has the function for the treatment of arimedex related bone joint symptoms, effect
Fruit is significant.Related bone joint symptoms refer to pain, osteoarthritis, hand rheumatoid arthritis.Chinese traditional medicine composition of the present invention
Object can reduce pain, improve arthralgia, stiff and function, improve hand joint pain, stiff and function.
Detailed description of the invention
Fig. 1 is BPI pain most severe degree trend chart；
Fig. 2 is BPI pain degree trend chart；
Fig. 3 is BPI pain relative influence trend chart；
Fig. 4 is WOMAC pain degree trend chart；
Fig. 5 is the stiff degree trend chart of WOMAC；
Fig. 6 is WOMAC function status trend chart；
Fig. 7 is M-SACRAH pain degree trend chart；
Fig. 8 is the stiff degree trend chart of M-SACRAH；
Fig. 9 is M-SACRAH function status trend chart.
Specific embodiment
Following experimental examples and embodiment are for further illustrating but being not limited to the present invention.
Experimental example 1: effect of the replenishing kidney and strengthening bone particle to breast cancer arimedex related bone joint symptoms
1, research method
1.1 researching and designings: multicenter, random, double blind, placebo controlled clinical research.
1.1.1 research center
All cases are in Beijing Chinese Medical Hospital, attached to Capital Medical Univ.'s oncology, Beijing Tumour Hospital's combination of Chinese tradiational and Western medicine
Section, China Academy of Sciences Guanganmen Hospital outpatient service and ward are completed.
1.1.2 random device
This research uses district's groups randomized.
1.1.3 blind designs
This research uses double-dummy design.
1.1.4 control setting
It is compareed between group between Chinese medicine group and control group；Treatment before with treatment after itself cross-reference.Placebo is by 95%
Dextrin and 5% wrinkled giant hyssop composition, to guarantee appearance, smell, the similarity degree of quality and taste.
1.2 research object
1.2.1 it is included in standard
(1) there is I-III primary breast cancer patient of clear pathological diagnosis, complete operation, chemicotherapy, confirm no tumour on inspection
Recurrence or transfer.
(2) Bones and joints symptom is occurred after taking third generation arimedex (Letrozole, Anastrozole, Exemestane)
(muscle skeletons such as arthralgia, myalgia, ostalgia, stiff joint symptoms), symptoms last 1 month, scale score >=3 point BPI-SF.
(3) Chinese medical discrimination meets kidney deficiency and liver, obstruction of the circulation of vital energy network resistance card (evaluation criterion is shown in annex).
(4) estimated life cycle is greater than 6 months.
(5) ECOG scoring is 0-2 points.
(6) informed consent form is signed in this research of voluntary participation.
1.3.2 exclusion criteria
(1) (such as hyperthyroidism, first subtract the chronic disease with endocrine system disease and influence bone metabolism, diabetes, Cushing are comprehensive
Sign, chronic liver disease, nephrosis, primary myeloma, bone tumour, Bone tumour etc.).
(2) taking except calcium remover within nearly 3 months influence bone metabolism drug (such as glucocorticoid, thyroid hormone,
Heparin, anticonvulsive drug, diuretics, bisphosphonates etc.) patient.
(3) there is Calcium and vitamin D to use contraindication person.
(4) specific primary osteoarthropathy patient is diagnosed.
(5) merge other organs primary tumo(u)r patient and intentionally, liver, the serious diseases such as kidney and hemopoietic system.
(6) gestation or history is mentally ill and patient that cognitive disorder can not be cooperated.
1.4 intervening measures:
1.4.1 basic medication regulation
It is all enter a group patient be both needed to take one of third generation arimedex and calcium carbonate D3 piece:
(1) Letrozole (Letrozol) trade name: furlong, 2.5mg/d is oral, Novartis Pharma AG；Or cottonrose hibiscus
Auspicious, 2.5mg/d is oral, Hengrui Medicine Co., Ltd., Jiangsu Prov..
(2) Anastrozole (Anastrozole) trade name: Arimidex, lmg/d is oral, AstraZeneca Co., Ltd.
(3) Exemestane (Exemestane) trade name: A Nuoxin, 25mg/d are oral, Pfizer Ltd..
(4) calcium carbonate D3 piece (Calclium Carbonate and Vitamin D3) trade name: Caltrate D tablet (calcium member
Plain 600mg+VitD3125IU/ piece): 2 tablet per days take orally, Wyeth pharmaceuticals.
1.4.2 Chinese medicine group
Replenishing kidney and strengthening bone particle (sample prepared by the method for using embodiment 1), each 1 time daily morning and evening, 1 bag (about every time
12g), warm boiled water.The course for the treatment of: 12 weeks.
1.4.3 control group
Placebo granulation, each 1 time daily morning and evening, every time 1 bag (about 12g), warm boiled water.The course for the treatment of: 12 weeks.
1.5 observations and index of assessment of curative effect
1.5.1 demographic data
1.5.2 tumour medical history
1.5.3 arimedex related bone joint symptoms
Patient's bone joint pain position, time of occurrence, severity, if there are morning stiffness, swelling, carpal tunnel syndrome and
Stuck-finger.
1.5.4 the regulation of time point is observed
1.5.5 index of assessment of curative effect
1.5.5.1 curative effect evaluation index
Brief Pain scale simplified version (Brief Pain Inventory-Short Form, BPI-SF): Brief Pain amount
Table (BPI) is developed by pain research group of neurology department of University of Wisconsin, is suitable for the Clinical Pain assessment of various people.?
It is deleted on the basis of this scale, obtains Brief Pain scale simplified version (BPI-SF), reliability and validity are by multinomial research
It is confirmed.BPI-SF is divided to for two main evaluation areas: pain degree (including the most slight journey of pain most severe degree, pain
Degree, the degree of pain average degree and current pain) and pain relative influence (including general activity, mood, walking ability, day
Often work, with his relationship, sleep and life interest).Scale problematic item mainly uses digit score method (NAS, 0-10 points) right
Patient pain's situation is assessed.Score is higher, and symptom is more serious.
1.5.5.2 secondary efficacy evaluation index
(1) western Ontario and Mike's Maas university Osteoarthritis Index (Western Ontario and McMaster
Universities Osteoarthritis Index, WOMAC Index): WOMAC index is taught by Nicholas Bellamy
It awards and its team designs, to assess the symptom and function of knee, hip joint.Scale shares 24 entries, is divided into three assessment necks
Domain: pain, stiff and function.It can need to select different appraisal procedures according to clinical or research: digit score method (NAS,
0-10), five point-score of visual analogue scales (VAS, 0-100mm) and Li Kete (5-point Likert, 1-5).
(2) hand rheumatoid arthritis assessment correction score (Modified Score for the Assessment and
Quantification of Chronic Rheumatoid Affections of the Hands, M-SACRAH): M-
SACRAH is the scale for assessing hand rheumatoid arthritis shape and function, is the simple version of SACRAH.The scale is divided into pain
Bitterly, stiff and three evaluation areas of function, share 12 problems, and each problem uses VAS methods of marking (0-100mm).
2. result of study
There is the patient with breast cancer of AIMSS to recruiting 146 altogether between in October, 2014 in August, 2013, by being included in, arranging
Screening and informed consent process except standard share 73 research objects and enter group.Wherein Chinese medicine group 38, control group 35.
Arthralgia is more universal (100%) in Bones and joints symptom, is secondly myalgia (48.05%), ostalgia is minimum
(27.27%), for 92.21% patient there are morning stiffness, there is stuck-finger in 27.27% patient, and only 9.09% patient suffers from
Carpal tunnel syndrome.Arthralgia predilection site is knee joint (90.91%), interphalangeal joint (72.73%) and metacarpophalangeal joints
(61.04%)；Myalgia focuses mostly in thigh (40.54%), lumbosacral region (37.84%) and arm (35.14%)；Ostalgia
Then it is more common in hipbone (57.14%)；Severity is mostly light moderate.The rush hour that AIMSS occurs is to take 7.16 after AIs
A month.
2.2 each index of assessment of curative effect compare (PPS)
2.2.1 Brief Pain scale (BPI-SF)
Through two sample t-tests, pain most severe degree: when baseline, Chinese medicine group and control group scoring are 6.18 ± 1.61 Hes
5.97 ± 1.40 (P=0.550), after treatment 12 weeks, Chinese medicine group declines 3.05 points, and control group declines 1.60 points (P=0.002).
Pain degree: when baseline, Chinese medicine group and control group scoring are 4.55 ± 1.25 and 4.25 ± 1.03 (P=0.264), treatment 12
Zhou Hou, Chinese medicine group decline 2.43 points, and control group declines 1.19 points (P=0.007).Pain relative influence: when baseline, Chinese medicine group
With control group average out to 4.51 ± 2.23 and 4.29 ± 1.79 (P=0.655), after treatment 12 weeks, Chinese medicine group declines 2.65 points,
Control group declines 1.24 points (P=0.001).
Each field scoring baseline is comparable (P > 0.05).After treating 12 weeks, either pain degree or pain
In terms of correlation function, Chinese medicine group improves obvious (P < 0.05) compared with control group.After follow-up 12 weeks, two groups of differences equally have statistics
It learns meaning (P < 0.05) (table 1, Fig. 1-3).
(PPS) is compared in 1 two groups of BPI-SF scorings of table
2.2.2 western Ontario and Mike's Maas university Osteoarthritis Index (WOMAC Index)
Through two sample t-tests, pain field: when baseline, 146.66 ± 86.87 He of Chinese medicine group and control group average out to
163.26 ± 72.05 (P=0.380), after treatment 12 weeks, Chinese medicine group decline 83.55, control group declines 35.03 (P=
0.002).Stiff field: when baseline, Chinese medicine group and the (P=of control group average out to 72.05 ± 43.99 and 82.60 ± 35.07
0.264) after, treating 12 weeks, Chinese medicine group decline 38.29, control group declines 19.69 (P=0.003).Functional area: when baseline,
Chinese medicine group and control group average out to 527.08 ± 289.82 and 594.34 ± 254.80 (P=0.298), after treatment 12 weeks, Chinese medicine
Group decline 317.19, control group declines 146.88 (P=0.000) (table 2, Fig. 4-6).
Two groups of baseline scores are comparable (P > 0.05).After treating 12 weeks, Chinese medicine group and control group arthralgia,
There is improvement in terms of stiff and function, Chinese medicine group improves obviously compared with control group, and difference has statistical significance (P < 0.05).With
After visiting 12 weeks, two groups of differences equally have statistical significance (P < 0.05).
(PPS) is compared in 2 two groups of WOMAC scorings of table
2.2.3 hand rheumatoid arthritis assessment correction score (M-SACRAH)
Through two sample t-tests, pain field: when baseline, 68.61 ± 42.13 He of Chinese medicine group and control group average out to
64.91 ± 43.97 (P=0.715), after treatment 12 weeks, Chinese medicine group decline 45.58, control group declines 16.42 (P=0.003).
Stiff field: when baseline, Chinese medicine group and control group average out to 87.71 ± 39.69 and 91.03 ± 39.50 (P=0.722) are controlled
After treating 12 weeks, Chinese medicine group decline 47.95, control group decline 27.06 (P=0.009) functional areas: when baseline, Chinese medicine group and
Control group average out to 97.95 ± 89.14 and 122.97 ± 140.80 (P=0.373), after treatment 12 weeks, the decline of Chinese medicine group
76.95, control group declines 46.57 (P=0.006) (table 3, Fig. 7-9).
Equal no difference of science of statistics (P > 0.05), is comparable when each field scoring baseline.After treating 12 weeks, two groups
There is improvement in terms of hand joint pain, stiff and function, Chinese medicine group improves obvious (P < 0.05) compared with control group.Follow-up 12 weeks
Afterwards, the statistical difference (P < 0.05) equally between three fields observed two groups.
(PPS) is compared in 3 two groups of M-SACRAH scorings of table
Embodiment 1
1, prescription:
Radix rehmanniae preparata 200g, pulp of dogwood fruit 150g, Semen Cuscutae 100g, 150 parts of radix cyathulae, rhizoma cyperi 100g, Radix Angelicae Sinensis 100g, Poria cocos
150g, Radix Paeoniae Alba 150g, Rhizoma Chuanxiong 100g, rhizoma corydalis 150g, lopseed 150g, caulis trachelospermi 200g.
2. preparation method:
Flavour of a drug add water to cook 2 times, first time 60min, the 2nd 30min, filter, and concentration adds right amount of auxiliary materials, mixes, and do
It is dry, granulation to get.
Embodiment 2
1, prescription:
Radix rehmanniae preparata 190g, pulp of dogwood fruit 170g, Semen Cuscutae 110g, radix cyathulae 120g, rhizoma cyperi 130g, Radix Angelicae Sinensis 120g, Poria cocos
170g, Radix Paeoniae Alba 130g, Rhizoma Chuanxiong 120g, rhizoma corydalis 130g, lopseed 160g, caulis trachelospermi 190g.
2. preparation method:
Flavour of a drug add water to cook 2 times, first time 60min, the 2nd 30min, filter, and concentration adds right amount of auxiliary materials, mixes, and do
It is dry, granulation to get.
Embodiment 3
1, prescription:
Radix rehmanniae preparata 180g, pulp of dogwood fruit 120g, Semen Cuscutae 80g, radix cyathulae 180g, rhizoma cyperi 140g, Radix Angelicae Sinensis 90g, Poria cocos 130g,
Radix Paeoniae Alba 170g, Rhizoma Chuanxiong 90g, rhizoma corydalis 170g, lopseed 130g, caulis trachelospermi 170g.
2. preparation method:
Flavour of a drug add water to cook 2 times, first time 60min, the 2nd 30min, filter, and concentration adds right amount of auxiliary materials, dry, add
Right amount of auxiliary materials mixes, granulation, packing capsule 100 to get.
Claims (8)
1. the drug that a kind of Chinese medicine composition of replenishing kidney and strengthening bone treats Bones and joints symptom caused by arimedex in preparation
In application, the Chinese medicine composition bulk pharmaceutical chemicals composition and parts by weight are as follows: 180-220 parts of radix rehmanniae preparata, 120-180 parts of pulp of dogwood fruit,
80-120 parts of Semen Cuscutae, 120-180 parts of radix cyathulae, 80-150 parts of rhizoma cyperi, 80-130 parts of Radix Angelicae Sinensis, 120-180 parts of Poria cocos, Radix Paeoniae Alba
120-180 parts, 80-130 parts of Rhizoma Chuanxiong, 120-180 parts of rhizoma corydalis, 120-180 parts of lopseed, 160-220 parts of caulis trachelospermi；The phase
It closes Bones and joints symptom and refers to pain, osteoarthritis, hand rheumatoid arthritis.
2. application as described in claim 1, it is characterised in that the bulk pharmaceutical chemicals of the pharmaceutical composition form and parts by weight are as follows: radix rehmanniae preparata
200 parts, 150 parts of pulp of dogwood fruit, 100 parts of Semen Cuscutae, 150 parts of radix cyathulae, 100 parts of rhizoma cyperi, 100 parts of Radix Angelicae Sinensis, 150 parts of Poria cocos, Radix Paeoniae Alba
150 parts, 100 parts of Rhizoma Chuanxiong, 150 parts of rhizoma corydalis, 150 parts of lopseed, 200 parts of caulis trachelospermi.
3. application as described in claim 1, it is characterised in that the bulk pharmaceutical chemicals of the pharmaceutical composition form and parts by weight are as follows: radix rehmanniae preparata
190 parts, 170 parts of pulp of dogwood fruit, 110 parts of Semen Cuscutae, 120 parts of radix cyathulae, 130 parts of rhizoma cyperi, 120 parts of Radix Angelicae Sinensis, 170 parts of Poria cocos, Radix Paeoniae Alba
130 parts, 120 parts of Rhizoma Chuanxiong, 130 parts of rhizoma corydalis, 160 parts of lopseed, 190 parts of caulis trachelospermi.
4. application as described in claim 1, it is characterised in that the bulk pharmaceutical chemicals of the pharmaceutical composition form and parts by weight are as follows: radix rehmanniae preparata
180 parts, 120 parts of pulp of dogwood fruit, 80 parts of Semen Cuscutae, 180 parts of radix cyathulae, 140 parts of rhizoma cyperi, 90 parts of Radix Angelicae Sinensis, 130 parts of Poria cocos, Radix Paeoniae Alba 170
Part, 90 parts of Rhizoma Chuanxiong, 170 parts of rhizoma corydalis, 130 parts of lopseed, 170 parts of caulis trachelospermi.
5. the application as described in Claims 1-4 is any, which is characterized in that the dosage form of composition is oral preparation.
6. application as claimed in claim 5, which is characterized in that the oral preparation include capsule, granule, tablet,
Pill, powder.
7. the application as described in Claims 1-4 is any, it is characterised in that composition the preparation method comprises the following steps: flavour of a drug add water to cook,
Filtration, concentration, adds right amount of auxiliary materials, mixes, dry, granulation to get.
8. the use as claimed in claim 7, it is characterised in that the preparation method comprises the following steps: flavour of a drug add water to cook 2 times, first time 60min,
2nd 30min is filtered, and concentration adds right amount of auxiliary materials, mixes, dry, granulation to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510530639.5A CN105168732B (en) | 2015-08-26 | 2015-08-26 | A kind of application of the Chinese medicine composition of replenishing kidney and strengthening bone in the drug that bone joint pain caused by arimedex is treated in preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510530639.5A CN105168732B (en) | 2015-08-26 | 2015-08-26 | A kind of application of the Chinese medicine composition of replenishing kidney and strengthening bone in the drug that bone joint pain caused by arimedex is treated in preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105168732A CN105168732A (en) | 2015-12-23 |
| CN105168732B true CN105168732B (en) | 2019-01-04 |
Family
ID=54891482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510530639.5A Expired - Fee Related CN105168732B (en) | 2015-08-26 | 2015-08-26 | A kind of application of the Chinese medicine composition of replenishing kidney and strengthening bone in the drug that bone joint pain caused by arimedex is treated in preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105168732B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7158831B2 (en) * | 2017-06-30 | 2022-10-24 | 小林製薬株式会社 | Tablet containing goshitsu processed material |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966253A (en) * | 2010-09-21 | 2011-02-09 | 山东欣博药物研究有限公司 | Tao hong si wu granule and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130058790A (en) * | 2011-11-28 | 2013-06-05 | 주식회사 진생사이언스 | Pharmaceutical composition comprising the extract of schizonepeta tenuifolia var. japonica for preventing and treating osteoporosis or promoting body growth |
-
2015
- 2015-08-26 CN CN201510530639.5A patent/CN105168732B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101966253A (en) * | 2010-09-21 | 2011-02-09 | 山东欣博药物研究有限公司 | Tao hong si wu granule and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 中医治疗膝骨关节炎研究进展;燕炼钢等;《中医药研究进展》;20090430;第21卷(第2期);第174-177页，尤其是第175页左栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105168732A (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038758B (en) | rheumatism preparation for treating rheumatism | |
| CN103735641B (en) | Medicine for the treatment of fracture and preparation method thereof | |
| CN101181568B (en) | Traditional chinese medicine preparation for curing osteoproliferation as well as arthrosis ache | |
| CN106236854A (en) | The Chinese medicine composition of a kind for the treatment of of arthritis and application thereof | |
| CN105168732B (en) | A kind of application of the Chinese medicine composition of replenishing kidney and strengthening bone in the drug that bone joint pain caused by arimedex is treated in preparation | |
| CN101912536B (en) | Medicinal composition for treating rheumatism and rheumatoid disease | |
| CN105079369B (en) | A kind of application of the Chinese medicine composition of replenishing kidney and strengthening bone in the drug that osteoporosis caused by arimedex is treated in preparation | |
| CN104189463A (en) | Rheumatism pain medicinal liquor and preparation method thereof | |
| CN105434679A (en) | Traditional Chinese medicine health-care preparation for reducing weight and slimming | |
| CN103610982A (en) | Medicine for treating rheumatic arthritis | |
| CN103393783B (en) | Composition containing resveratrol and application | |
| CN102872287A (en) | Traditional Chinese medicine composition for treating femoral head necrosis and preparation method thereof | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN105168731A (en) | Pharmaceutical composition treating osteoporosis and preparation method thereof | |
| CN103623085B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN106822271A (en) | It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use | |
| CN105147932B (en) | A kind of replenishing kidney and strengthening bone Chinese medicine composition and preparation method thereof | |
| CN104208318A (en) | Traditional Chinese medicine preparation for treating apoplectic sequela and preparation method of traditional Chinese medicine preparation | |
| CN107080798B (en) | Plaster for dredging collaterals and preparation method thereof | |
| CN105169352A (en) | Externally applied traditional Chinese medicinal analgetic for treating pains due to wind-damp arthritis | |
| CN104001031A (en) | Medicament for treating asthma | |
| CN104491292A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating osteoporosis | |
| CN103751634B (en) | A kind ofly treat high medicine of spleen and preparation method thereof | |
| CN104547086A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN103656523A (en) | Traditional Chinese medicine tablet capable of relaxing meridian and activating blood circulation and preparation method of tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190104 Termination date: 20210826 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |